Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | Business Wire
Puma Biotechnology (NASDAQ:PBYI) Shares Up 5.5% - Opera News
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology (PBYI) Stock Price, News & Info | The Motley Fool
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
$46.06 Million in Sales Expected for Puma Biotechnology, Inc. (NASDAQ:PBYI) This Quarter - Defense World
Puma Biotechnology (NASDAQ:PBYI) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS - Defense World
Puma Biotechnology (NASDAQ:PBYI) Has Debt But No Earnings; Should You Worry?
FinData: Share Price for NASDAQ, PBYI - Puma Biotechnology
Puma Biotechnology, Inc. 2021 Q2 - Results - Earnings Call Presentation ( NASDAQ:PBYI) | Seeking Alpha
PBYI | Puma Biotechnology Inc. Stock Overview (U.S.: Nasdaq) | Barron's
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
PBYI Institutional Ownership - Puma Biotechnology Inc (NASDAQ) Stock
Puma Biotechnology (PBYI) Stock Price, News & Info | The Motley Fool
Market Sentiment Around Loss-Making Puma Biotechnology, Inc. (NASDAQ:PBYI)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | IQ Stock Market
PBYI | Puma Biotechnology Inc. Stock Overview (U.S.: Nasdaq) | Barron's
التاريخ مذكرة فعالة puma pharma stock price - daydreema.com
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space ( NASDAQ:PBYI) | Seeking Alpha
PBYI | Puma Biotechnology Inc. Stock Overview (U.S.: Nasdaq) | Barron's
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | citybiz
Puma Biotechnology (NASDAQ:PBYI) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS - Defense World
Analysts Have Made A Financial Statement On Puma Biotechnology, Inc.'s ( NASDAQ:PBYI) First-Quarter Report
